Research progress of biomarkers in the prediction of anti-PD-1/PD-L1 immunotherapeutic efficiency in lung cancer

Currently, anti-PD-1/PD-L1 immunotherapy using immune checkpoint inhibitors is widely used in the treatment of multiple cancer types including lung cancer, which is a leading cause of cancer death in the world. However, only a limited proportion of lung cancer patients will benefit from anti-PD-1/PD...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Luyao Wang, Zongxing Yang, Fucheng Guo, Yurong Chen, Jiarui Wei, Xiangpeng Dai, Xiaoling Zhang
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-07-01
Edice:	Frontiers in Immunology
Témata:	lung cancer biomarker anti-PD-1/PD-L1 immunotherapy immune checkpoint dMMR/MSI CtDNA
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1227797/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!